Aerosolized Measles Vaccine Fails Noninferiority Trial in India

Although aerosolized measles vaccine was immunogenic, its seropositivity rate was 9.2 percentage points lower than that of subcutaneous vaccine, exceeding the prespecified 5 percentage point noninferiority margin.

Measles vaccine is usually given by subcutaneous injection. An aerosolized measles vaccine (AMV) could be administered by individuals with less training and would not require sterile needles and syringes. The technology has been developed, but previous trials comparing AMV with conventional subcutaneous measles vaccine (SMV) have shown inconsistent efficacy results. A new study, performed at eight primary care clinics in India, was designed to determine whether AMV would be noninferior to SMV — defined as ≤5 percentage points lower — in inducing a protective immune response in infants.

In this open-label trial, 2004 infants aged 9.0 to 11.9 months were randomized to receive WHO-licensed measles vaccine, produced by the Serum Institute of Ind…

Reviewing Author

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Aerosolized Measles Vaccine Fails Noninferiority Trial in India

Topics

Reviewing Author